Stephanie S. O'MAlley

Stephanie S. O'MAlley

Auto-generated profile, based on publicly available information

Stephanie S. O'MAlley

Department of Psychiatry Yale School of Medicine New Haven Connecticut USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 February 2010 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
RLRobert F. Leeman
Robert F. Leeman
MHMarkus Heilig
Markus Heilig
CCChristopher L. Cunningham
Christopher L. Cunningham
DSDavid N. Stephens
David N. Stephens
TDTheodora Duka
Theodora Duka
SOStephanie S. O'MAlley
Stephanie S. O'MAlley

28 July 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SOStephanie S. O'Malley
Stephanie S. O'Malley
BRBruce J. Rounsaville
Bruce J. Rounsaville
CFConor Farren
Conor Farren
KNKee Namkoong
Kee Namkoong
RWRan Wu
Ran Wu
POPatrick G. O'Connor
Patrick G. O'Connor
PROBLEM DRINKING is prevalent in primary care settings, and general internists and other primary care physicians are uniquely suited to identify and treat problem drinkers.1,2 In one study3 of primary care patients, 1 of 6 were problem drinkers, and in another study,4 30% of drinkers met criteria for alcohol dependence. Strategies for addressing alcohol problems in primary care have focused on screening and referral to treatment.5 Research6,7 suggests that primary care physicians may help nondependent patients reduce alcohol consumption by using brief counseling techniques. A recent randomized trial3 performed in physicians' offices demonstrated that drinking and health resource utilization can be decreased with the use of brief physician advice. Although these studies showed the benefits of brief counseling for nondependent problem drinkers, alcohol-dependent patients were generally excluded. Thus, the role of general internists and other primary care physicians in the treatment of alcohol dependence is uncertain.

11 January 2011 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
LFLisa M Fucito
Lisa M Fucito
BTBenjamin A. Toll
Benjamin A. Toll
RWRan Wu
Ran Wu
DRDenise M. Romano
Denise M. Romano
ETEce Tek
Ece Tek
SOStephanie S. O’mAlley
Stephanie S. O’mAlley

1 October 2007 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
SOStephanie S. O'MAlley
Stephanie S. O'MAlley
JGJames C. Garbutt
James C. Garbutt
DGDavid R. Gastfriend
David R. Gastfriend
QDQunming Dong
Qunming Dong
HKHenry R. Kranzler
Henry R. Kranzler
Extended-release naltrexone (XR-NTX) is a once-a-month injectable formulation that is Food and Drug Administration-approved for the treatment of alcohol dependence in patients able to abstain from alcohol before treatment initiation. This paper presents the results of an analysis of efficacy data from a subgroup of patients with 4 days or more of voluntary abstinence before treatment initiation (n = 82) on a wide range of drinking-related outcomes. In these patients, all of whom received counseling, the rate of abstinence was severalfold higher for XR-NTX 380 mg compared with placebo: median time to first drink was 41 days versus 12 days, respectively; rate of continuous abstinence at end of the study was 32% versus 11% (P = 0.02). Extended-release naltrexone 380 mg, compared with placebo, substantially increased time to first heavy drinking event (>180 days vs 20 days; P = 0.04) and decreased the median number of any drinking days per month by 90% (0.7 vs 7.2; P = 0.005) and heavy drinking days per month by 93% (0.2 days vs 2.9 days; P = 0.007). The XR-NTX 380 mg group also had more than twice as many responders compared with placebo (70% vs 30%; P = 0.006; responder defined as having no more than 2 heavy drinking days in any consecutive 28-day period) and experienced greater improvement in gamma-glutamyl transpeptidase levels (P = 0.03). Outcomes for XR-NTX 190 mg (n = 26) were generally intermediate, demonstrating a dose-response effect. In conclusion, XR-NTX 380 mg prolonged abstinence and reduced the number of heavy drinking days and drinking days in patients who were abstinent for as few as 4 days before treatment initiation.

27 March 2006 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
SOStephanie S. O’malley
Stephanie S. O’malley
JCJudith L. Cooney
Judith L. Cooney
SKSuchitra Krishnan-Sarin
Suchitra Krishnan-Sarin
JDJoel A. Dubin
Joel A. Dubin
SMSherry A. McKee
Sherry A. McKee
PJPeter Jatlow
Peter Jatlow
Research from JAMA Internal Medicine — A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation